State of Alaska Department of Revenue Decreases Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

State of Alaska Department of Revenue lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 7.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 20,063 shares of the specialty pharmaceutical company’s stock after selling 1,563 shares during the period. State of Alaska Department of Revenue’s holdings in Collegium Pharmaceutical were worth $617,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Pacer Advisors Inc. increased its holdings in Collegium Pharmaceutical by 68.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after purchasing an additional 883,380 shares during the period. Natixis Advisors L.P. increased its holdings in Collegium Pharmaceutical by 152.9% during the 3rd quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 32,865 shares during the period. Loomis Sayles & Co. L P increased its holdings in Collegium Pharmaceutical by 32.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after purchasing an additional 67,439 shares during the period. Barclays PLC increased its holdings in Collegium Pharmaceutical by 16.9% during the 3rd quarter. Barclays PLC now owns 39,593 shares of the specialty pharmaceutical company’s stock valued at $886,000 after purchasing an additional 5,713 shares during the period. Finally, Ritholtz Wealth Management purchased a new position in Collegium Pharmaceutical during the 4th quarter valued at about $286,000.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on COLL shares. Jefferies Financial Group restated a “hold” rating and set a $37.00 price target (up previously from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Friday, March 29th. Piper Sandler reiterated an “overweight” rating and set a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Truist Financial upped their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 23,560 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $32.28, for a total value of $760,516.80. Following the sale, the executive vice president now directly owns 111,322 shares of the company’s stock, valued at approximately $3,593,474.16. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.69% of the company’s stock.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $36.39 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. The business’s 50 day moving average price is $36.63 and its 200-day moving average price is $30.30. Collegium Pharmaceutical, Inc. has a 52 week low of $20.83 and a 52 week high of $40.95. The stock has a market cap of $1.19 billion, a P/E ratio of 30.84 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The firm had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. Equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.